<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519854</url>
  </required_header>
  <id_info>
    <org_study_id>P05940</org_study_id>
    <secondary_id>MK-8616-020</secondary_id>
    <secondary_id>19.4.202</secondary_id>
    <nct_id>NCT03519854</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics of Org 25969 (MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).</brief_title>
  <official_title>A Multi-center, Randomized, Assessor-blinded, Placebo Controlled, Phase II, Parallel Dose-finding Trial in Male Subjects of ASA 1-2 to Assess the Efficacy, Safety and Pharmacokinetics of 5 Doses of Org 25969 When Administered After 0.6 mg.Kg-1 Esmeron® at 3, 5 or 15 Minutes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy, safety, and pharmacokinetics of Org 25969 (MK-8616)
      when administered for the reversal of neuromuscular blockade in male participants receiving
      surgery, classified as American Society of Anesthesiologists (ASA) class 1 (otherwise normal,
      healthy participant) to class 2 (participant with mild systemic disease). The primary
      objective of this study is to explore the dose-response relation of MK-8616 given as a
      reversal agent at 3, 5, or 15 minutes following administration of 0.6 mg/kg Esmeron®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2002</start_date>
  <completion_date type="Actual">June 1, 2003</completion_date>
  <primary_completion_date type="Actual">June 1, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Predose and at 2 and 30 minutes following MK-8616 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected QT Interval (QTc)</measure>
    <time_frame>Predose and at 2 and 30 minutes following MK-8616 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event</measure>
    <time_frame>Up to 7 days following MK-8616 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (1 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (2 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (4 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (6 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (8 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (1 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (2 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (4 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (6 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (8 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (1 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (2 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (4 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (6 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8616 (8 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8616 (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).</description>
    <arm_group_label>Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Placebo; given 15 minutes after Esmeron®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8616</intervention_name>
    <description>MK-8616 administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.</description>
    <arm_group_label>MK-8616 (1 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (1 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (1 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <other_name>Org 25969; Sugammadex; Bridion®.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmeron®</intervention_name>
    <description>Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.</description>
    <arm_group_label>Placebo; given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (1 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 3 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Placebo; given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (1 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 5 minutes after Esmeron®</arm_group_label>
    <arm_group_label>Placebo; given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (1 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (2 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (4 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (6 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <arm_group_label>MK-8616 (8 mg/kg); given 15 minutes after Esmeron®</arm_group_label>
    <other_name>Rocuronium bromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of ASA class 1 to 2.

          -  Participants scheduled for surgical procedures with an anticipated duration of
             anesthesia of at least 75 minutes, without further need for muscle relaxation other
             than for intubation.

        Exclusion Criteria:

          -  Participants in whom a difficult intubation because of anatomical malformations is
             expected.

          -  Participants known or suspected to have neuromuscular disorders and/or significant
             hepatic or renal dysfunction.

          -  Participants known or suspected to have a (family) history of malignant hyperthermia.

          -  Participants known or suspected to have an allergy to narcotics, muscle relaxants or
             other medication used during general anesthesia.

          -  Participants receiving medication known to interfere with neuromuscular blocking
             agents such as anticonvulsants, aminoglycosides, and Mg^2+.

          -  Participants who have already participated in this trial.

          -  Participants who have participated in another clinical trial, not pre-approved by NV
             Organon, within 30 days of entering into this trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

